CapsoVision Reports 10% Revenue Growth to $3.6 Million in Q2 2026

CapsoVision, Inc. reported its financial results for the second quarter of 2026, revealing a net revenue of $3.6 million, a 10% increase from $3.3 million in the same period last year. For the first half of 2026, the company generated $6.4 million in revenue, up 6% from $6.1 million in the prior year. The growth in revenue was primarily driven by a 13% increase in the number of CapsoCam Plus capsules sold, although this was partially offset by a 3% decrease in average selling prices due to competitive pressures. The gross profit for the quarter was $1.9 million, resulting in a gross margin of 51%, down from 55% in the previous year.

Operating expenses for the second quarter rose significantly, totaling $9.5 million, a 46% increase compared to $6.5 million in the same quarter of 2025. This increase was largely attributed to higher research and development costs, which surged by 57% to $5.3 million, reflecting ongoing clinical trials and development efforts, including a partnership with Canon Inc. for new imaging technology. General and administrative expenses also rose by 80% to $2.2 million, driven by costs associated with operating as a public company and increased stock-based compensation. The company reported an operating loss of $7.6 million for the quarter, compared to a loss of $4.7 million in the prior year.

CapsoVision's accumulated deficit reached $170.2 million as of June 30, 2026, and the company continues to face challenges in achieving profitability. The net loss for the second quarter was $7.5 million, a 62% increase from the $4.6 million loss reported in the same period last year. The company attributed its ongoing losses to high operating expenses and the costs associated with its research and development initiatives.

In terms of strategic developments, CapsoVision is actively working on expanding its product offerings, including the CapsoCam Colon capsule, which is expected to enter the market following FDA clearance anticipated in late 2026. The company is also focusing on enhancing its AI capabilities to improve diagnostic accuracy and efficiency in its products. As of June 30, 2026, CapsoVision had approximately $9.1 million in cash and cash equivalents, which the company believes may not be sufficient to fund its operations for the next 12 months without additional capital.

Looking ahead, CapsoVision plans to continue investing in research and development to support the commercialization of its products and expand its market presence. The company is also exploring additional funding options to ensure it can meet its operational needs and growth objectives. However, there remains substantial doubt about its ability to continue as a going concern without securing further financing.